International Cannabis Weekly: 143

• Online cannabis sales jump 600% in Ontario following COVID-19 restrictions.
• Washington D.C. to allow medical cannabis deliveries during lockdown.
• US hemp groups ask federal regulators to include hemp farmers in COVID-19 relief.
• Coronavirus delays adult-use legalisation in Guam.
• Danish Medicines Agency puts all inspections on hold until the summer.

• Virginia decriminalises cannabis but low-level penalties remain in place.
• Read key insights from The Oceania Cannabis Report: Second Edition.
• New DEA figures show more cannabis seizures but fewer cannabis arrests in 2019.

• German cannabis association calls on federal ministers to regulate product prices.
• DanCann secures US$3.48 million investment to develop its facility in Denmark.
• AMP German Cannabis Group obtains licences needed for European imports.

• Aurora plans to consolidate its shares to retain NYSE public listing.
• Cannabis retailers in Ottawa praise decision to allow cannabis deliveries.
• HEXO raises US$33 million in public offering.

• Judge upholds temporary ban on recreational cannabis sales in Massachusetts.
• Canopy Growth closes multiple international operations.
• Florida hemp licence applications to open by 27 April.
• Montana activists sue state officials for the right to collect electronic signatures.
• Cannabis Beverage Association forms to educate policymakers and consumers.
• Molson Coors and HEXO form joint venture to explore non-alcoholic CBD beverages.

• Minister for Health praises LYPHE Group’s first Australian import into the UK.
• New Zealand’s Cannasouth announces opening of US$1.8 million share purchase plan.
• Sequoya Cannabis secures US$1.2 million investment from Australia’s MMJ Group.

• US court upholds US$4 million judgement in favour of El-Salvador-based CBD firm.
• BD Vida partners with Iowa manufacturer to deliver medical CBD products in Brazil.

• Israeli cultivator passes microbial and pesticide testing without using irradiation.
• Labat Africa to acquire 70% of Biodata to expand available research infrastructure.

• Headache and migraine pain approximately halved by cannabis, finds new analysis.
• Cannabis ‘clinically meaningful’ in treating opioid withdrawal symptoms.
• Study finds that access to cannabis reduces opioid demand.

• Researchers build human brain model to study the effects of psilocybin.
  
• Champignon Brands appoints former Red Bull Canada president to advisory committee.
• US biotech company files provisional patent application for psilocybin product.
• Mindset Pharma begins preclinical work on novel psychedelics.
• Australian charity suggests using psychedelic therapy to treat mental health issues.

Prohibition Partners is proud to launch The Oceania Cannabis Report: Second Edition. The report contains expert analysis on the latest industry developments across Australia, New Zealand and the surrounding islands, which is set to be worth $US1.55 billion by 2024.

Download your free copy of the report, here.